Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Am J Otolaryngol ; 43(1): 103170, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34391165

RESUMEN

PURPOSE: New-onset olfactory and gustatory dysfunction (OGD) represents a well-acknowledged COVID-19 red flag. Nevertheless, its clinical, virological and serological features are still a matter of debate. MATERIALS AND METHODS: For this cohort study, 170 consecutive subjects with new-onset OGD were consecutively recruited. Otolaryngological examination, OGD subjective grading, nasopharyngeal swabs (NS) for SARS-CoV-2 RNA detection and serum samples (SS) collection for SARS-CoV-2 IgG quantification were conducted at baseline and after one (T1), two (T2) and four weeks (T3). RESULTS: SARS-CoV-2 infection was confirmed in 79% of patients. Specifically, 43% of positive patients were detected only by SS analysis. The OGD was the only clinical complaint in 10% of cases. Concurrent sinonasal symptoms were reported by 45% of patients. Subjective improvement at T3 was reported by 97% of patients, with 40% recovering completely. Hormonal disorders and RNA detectability in NS were the only variables associated with OGD severity. Recovery rate was higher in case of seasonal influenza vaccination, lower in patients with systemic involvement and severe OGD. Not RNA levels nor IgG titers were correlated with recovery. CONCLUSION: Clinical, virological and serological features of COVID-19 related OGD were monitored longitudinally, offering valuable hints for future research on the relationship between host characteristics and chemosensory dysfunctions.


Asunto(s)
COVID-19/complicaciones , Trastornos del Olfato/inmunología , Trastornos del Olfato/virología , Trastornos del Gusto/inmunología , Trastornos del Gusto/virología , Adulto , Femenino , Humanos , Inmunoglobulina G/inmunología , Masculino , Persona de Mediana Edad , SARS-CoV-2/inmunología
2.
J Int Adv Otol ; 15(1): 165-168, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30924777

RESUMEN

Hemangioma of the facial nerve (FN) is a very rare benign tumor whose origin is the vascular plexi that surround the nerve. The transpetrous, retrosigmoid, and middle cranial fossa (MCF) routes are the traditional and most widely used approaches to reach these lateral skull base neoformations. However, this very complex region can be reached through an exclusive transcanal endoscopic procedure in selected cases. One of these was a 42-year-old patient who had been presenting a worsening left FN paralysis (grade VI according to the House-Brackmann scale at the time of visit) for 22 months without a history of trauma or infection. Radiological studies showed a lesion in the region of the geniculate ganglion. A suprageniculate endoscopic approach was performed to remove the lesion, with the sacrifice of the FN and a simultaneous hypoglossal-facial anastomosis. The aim of this minimally invasive surgery is the complete excision of the disease, maintaining the hearing function intact and restoration of facial function, whenever possible, avoiding more invasive approaches.


Asunto(s)
Nervio Facial/trasplante , Ganglio Geniculado/irrigación sanguínea , Ganglio Geniculado/cirugía , Hemangioma/cirugía , Adulto , Anastomosis Quirúrgica , Audiometría de Tonos Puros , Fosa Craneal Media/diagnóstico por imagen , Fosa Craneal Media/patología , Fosa Craneal Media/cirugía , Oído Medio/patología , Oído Medio/cirugía , Endoscopía/métodos , Nervio Facial/irrigación sanguínea , Nervio Facial/patología , Parálisis Facial/etiología , Ganglio Geniculado/diagnóstico por imagen , Ganglio Geniculado/patología , Audición/fisiología , Hemangioma/patología , Humanos , Procedimientos Quirúrgicos Mínimamente Invasivos/métodos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA